trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Methimazole can cause fetal harm when administered during the first trimester of pregnancy.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
2 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Methimazole can cause fetal harm when administered during the first trimester of pregnancy?

Yes. Methimazole administration during the first trimester of pregnancy is associated with an increased risk of fetal harm and congenital malformations, leading clinical guidelines to favor safer alternatives like propylthiouracil.

Verdict: SUPPORTED · 2 sources for, 0 against · Last checked

The analysis

The retrieved literature, including a meta-analysis and clinical case reports, directly supports the claim that methimazole use during the first trimester of pregnancy increases the risk of congenital anomalies and fetal harm compared to alternatives like propylthiouracil.

Evidence for · 2
Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis.
2023
A systematic review and meta-analysis indicates that pregnant women treated with methimazole face a higher risk of congenital anomalies compared to those treated with propylthiouracil.
Get citation
Y, L., Q, L., Y, X., Y, C., & Y, M. (2023). Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis.. doi.org. https://doi.org/10.1371/journal.pone.0286097

See more details
More for · 1
A Case of Aplasia Cutis Congenita in the Setting of Maternal Carbimazole Use in the First Trimester.
2023
A clinical case report reinforces the association between maternal methimazole or carbimazole use in the first trimester and specific congenital defects such as aplasia cutis congenita.
Get citation
C, M., N, O., MC, D., & MA, B. (2023). A Case of Aplasia Cutis Congenita in the Setting of Maternal Carbimazole Use in the First Trimester.. doi.org. https://doi.org/10.1210/jcemcr/luad130

What does the evidence say?

The retrieved literature, including a meta-analysis and clinical case reports, directly supports the claim that methimazole use during the first trimester of pregnancy increases the risk of congenital anomalies and fetal harm compared to alternatives like propylthiouracil.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work